Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 10;12:1024956. doi: 10.3389/fonc.2022.1024956

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Xiong, Chen, Yang, Ma, Wang, Zhang, Yuan, Peng, Li and Luo

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

The immunotherapeutic prognosis for risk-dependent groups. (A–D). The negative association of patients’ risk scores with IC50 values for chemotherapeutics. (E–H). IC50 values for chemotherapeutics in the HRS group were higher compared to the LRS group. (I–L). The negative association of patients’ risk scores with the IC50 values of chemotherapeutics. (M–P). The IC50 values of chemotherapeutic agents were lower in the HRS group compared to the LRS group. (Q). The expression levels of 18 checkpoints in various risk categories. *p< 0.05, **p< 0.01, and ***p< 0.001.